| __timestamp | BioCryst Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 13608000 | 1777824000000 |
| Thursday, January 1, 2015 | 48257000 | 1807378000000 |
| Friday, January 1, 2016 | 26353000 | 1732051000000 |
| Sunday, January 1, 2017 | 25186000 | 1770531000000 |
| Monday, January 1, 2018 | 20653000 | 2097224000000 |
| Tuesday, January 1, 2019 | 48835000 | 3291188000000 |
| Wednesday, January 1, 2020 | 17812000 | 3197812000000 |
| Friday, January 1, 2021 | 157170000 | 3569006000000 |
| Saturday, January 1, 2022 | 270827000 | 4027478000000 |
| Sunday, January 1, 2023 | 331412000 | 4263762000000 |
| Monday, January 1, 2024 | 4263762000000 |
Unlocking the unknown
In the ever-evolving landscape of pharmaceuticals, revenue growth is a key indicator of a company's success. Over the past decade, Takeda Pharmaceutical Company Limited and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories. Takeda, a global leader, has consistently demonstrated robust growth, with its revenue surging by approximately 140% from 2014 to 2023. In contrast, BioCryst, a smaller player, has seen its revenue grow by over 2300% during the same period, albeit from a much smaller base.
Takeda's revenue reached a peak of approximately $4.26 trillion in 2023, reflecting its strong market presence and strategic acquisitions. Meanwhile, BioCryst's revenue, though significantly smaller, has shown impressive growth, peaking at around $331 million in 2023. This stark difference highlights the diverse strategies and market positions of these two companies.
Despite missing data for 2024, the trends indicate a promising future for both companies, with Takeda maintaining its dominance and BioCryst continuing its upward trajectory.
Comparing Revenue Performance: Gilead Sciences, Inc. or BioCryst Pharmaceuticals, Inc.?
Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc.: A Comprehensive Revenue Analysis
Breaking Down Revenue Trends: Takeda Pharmaceutical Company Limited vs Pharming Group N.V.
Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.: Examining Key Revenue Metrics
Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: A Comprehensive Revenue Analysis
Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated: Examining Key Revenue Metrics
Takeda Pharmaceutical Company Limited vs Dynavax Technologies Corporation: Annual Revenue Growth Compared
Incyte Corporation and BioCryst Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Insights: PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. Performance Compared
Revenue Insights: HUTCHMED (China) Limited and BioCryst Pharmaceuticals, Inc. Performance Compared
Arrowhead Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Revenue Insights: Galapagos NV and BioCryst Pharmaceuticals, Inc. Performance Compared